Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > surprised in a good way

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Feb 18, 2021 10:52am

141 Views

Post# 32595362

RE:RE:RE:surprised in a good way

Crunch5555 wrote: Theres a restriction to that stock..cant sell it right away

There might be some restrictions but it would no be forever. Sooner or later, it will play an important role to drive the share price. At a price of $6.30 = 5% near term profits - 1% loan from bank = 4% risk-free profit + warrants for free. It is still a very good deal.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing